Deborah Dunsire, Lundbeck
September 24, 2019 07:05 AM EDTUpdated 07:09 PM
Deals

Lund­beck’s Deb­o­rah Dun­sire didn’t just want an ex-US deal for Alder’s mi­graine drug. She want­ed the whole world

John Carroll

Editor & Founder

Lit­tle Alder had no prob­lem lin­ing up 10 drug com­pa­nies in­ter­est­ed in bid­ding for the ex-US rights to its CGRP mi­graine drug — the last place …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times